

Juan D Caete

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6637243/juan-d-canete-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

201
papers

4,877
citations

38
h-index

60
g-index

225
ext. papers

5,831
ext. citations

3.5
avg, IF

5.17
L-index

#	Paper	IF	Citations
201	Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 99-109		216
200	Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2004 , 63, 1594-600	2.4	214
199	Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. <i>Arthritis Research</i> , 2005 , 7, R569-80		182
198	Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. <i>Annals of the Rheumatic Diseases</i> , 2003 , 62, 897-900	2.4	157
197	Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 751-6	2.4	112
196	Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2004 , 50, 1636-41		112
195	Synovial tissue research: a state-of-the-art review. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 463-475	8.1	107
194	Ectopic lymphoid neogenesis in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 720-6	2.4	99
193	B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. <i>Journal of Immunology</i> , 2008 , 181, 785-94	5.3	91
192	Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. <i>Autoimmunity Reviews</i> , 2020 , 19, 102429	13.6	91
191	Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1751-5	2.4	84
190	Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1547-52	2.4	77
189	Small-vessel vasculitis surrounding a spared temporal artery: clinical and pathological findings in a series of twenty-eight patients. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1387-95		76
188	Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2004 , 31, 40-6	4.1	71
187	Urine metabolome profiling of immune-mediated inflammatory diseases. <i>BMC Medicine</i> , 2016 , 14, 133	11.4	67
186	Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1861-4	2.4	64
185	Immature blood vessels in rheumatoid synovium are selectively depleted in response to anti-TNF therapy. <i>PLoS ONE</i> , 2009 , 4, e8131	3.7	62

184	Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2008 , 37, 299-306	5.3	61
183	2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. <i>Reumatología Clínica</i> , 2015 , 11, 279-94	0.9	60
182	Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes. <i>Human Molecular Genetics</i> , 2012 , 21, 4549-57	5.6	60
181	Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. <i>Arthritis Research and Therapy</i> , 2012 , 14, R93	5.7	51
180	Muscle involvement in rheumatoid arthritis: clinicopathological study of 21 symptomatic cases. <i>Seminars in Arthritis and Rheumatism</i> , 1996 , 25, 421-8	5.3	51
179	The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population. <i>Scandinavian Journal of Rheumatology</i> , 2012 , 41, 10-4	1.9	50
178	Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis?. <i>British Journal of Rheumatology</i> , 2003 , 42, 972-5		50
177	Polymyalgia rheumatica: a syndrome associated with HLA-DR4 antigen. <i>Arthritis and Rheumatism</i> , 1988 , 31, 678-82		49
176	Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. <i>Rheumatology</i> , 2015 , 54, 1200-9	3.9	48
175	Palindromic rheumatism and other relapsing arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2004 , 18, 647-61	5.3	48
174	An unexpectedly high frequency of MEFV mutations in patients with anti-citrullinated protein antibody-negative palindromic rheumatism. <i>Arthritis and Rheumatism</i> , 2007 , 56, 2784-8		47
173	Synovial fibroblast hyperplasia in rheumatoid arthritis: clinicopathologic correlations and partial reversal by anti-tumor necrosis factor therapy. <i>Arthritis and Rheumatism</i> , 2011 , 63, 2575-83		45
172	Diagnostic usefulness of synovial vascular morphology in chronic arthritis. A systematic survey of 100 cases. <i>Seminars in Arthritis and Rheumatism</i> , 2003 , 32, 378-87	5.3	45
171	Etanercept in the longterm treatment of patients with ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2009 , 36, 1256-64	4.1	43
170	Distinct synovial immunopathology in Behçet disease and psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2009 , 11, R17	5.7	42
169	Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. <i>Clinical Rheumatology</i> , 2007 , 26, 1111-8	3.9	42
168	The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. <i>Arthritis and Rheumatism</i> , 2001 , 44, 66-72		42
167	Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 173	5.7	41

166	Patients with rheumatoid arthritis in clinical remission and ultrasound-defined active synovitis exhibit higher disease activity and increased serum levels of angiogenic biomarkers. <i>Arthritis Research and Therapy</i> , 2014 , 16, R5	5.7	39
165	Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. <i>Arthritis Care and Research</i> , 2013 , 65, 2024-31	4.7	38
164	Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2. <i>International Immunology</i> , 2004 , 16, 169-77	4.9	38
163	Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions. <i>International Ophthalmology</i> , 2010 , 30, 577-81	2.2	36
162	Radiological progression in early rheumatoid arthritis after DMARDs: a one-year follow-up study in a clinical setting. <i>British Journal of Rheumatology</i> , 2003 , 42, 1044-9		34
161	Successful treatment with infliximab in a patient with Diffuse Subretinal Fibrosis syndrome. <i>American Journal of Ophthalmology</i> , 2007 , 143, 533-4	4.9	33
160	Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease?. <i>Clinical Rheumatology</i> , 2012 , 31, 1047-50	3.9	32
159	Effects of smoking on disease activity and radiographic progression in early rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2011 , 38, 2536-9	4.1	32
158	Clinicopathological correlations of podoplanin (gp38) expression in rheumatoid synovium and its potential contribution to fibroblast platelet crosstalk. <i>PLoS ONE</i> , 2014 , 9, e99607	3.7	32
157	Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2009 , 11, R135	5.7	31
156	Antibodies to citrullinated human fibrinogen synthetic peptides in diagnosing rheumatoid arthritis. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 3573-84	8.3	31
155	Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. <i>Archivos De Bronconeumologia</i> , 2011 , 47, 208-12	0.7	30
154	Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors. <i>Arthritis Care and Research</i> , 2016 , 68, 899-906	4.7	30
153	Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 386-90	5.3	29
152	High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). <i>Rheumatology</i> , 2011 , 50, 1828-37	3.9	29
151	p53 expression in rheumatoid and psoriatic arthritis synovial tissue and association with joint damage. <i>Annals of the Rheumatic Diseases</i> , 2005 , 64, 183-7	2.4	29
150	Senescent synovial fibroblasts accumulate prematurely in rheumatoid arthritis tissues and display an enhanced inflammatory phenotype. <i>Immunity and Ageing</i> , 2019 , 16, 29	9.7	28
149	Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. <i>Arthritis Research and Therapy</i> , 2016 , 18, 160	5.7	28

148	Immunopathologic characterization of ultrasound-defined synovitis in rheumatoid arthritis patients in clinical remission. <i>Arthritis Research and Therapy</i> , 2016 , 18, 74	5.7	27
147	Carbon nanotube composite peptide-based biosensors as putative diagnostic tools for rheumatoid arthritis. <i>Biosensors and Bioelectronics</i> , 2011 , 27, 113-8	11.8	27
146	The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 757-764	5.3	27
145	Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, 991-7	2.2	27
144	Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. <i>British Journal of Dermatology</i> , 2017 , 176, 643-649	4	26
143	Rheumatoid arthritis: a clinical overview of new diagnostic and treatment approaches. <i>Current Topics in Medicinal Chemistry</i> , 2013 , 13, 698-704	3	26
142	Palindromic rheumatism with positive anticitrullinated peptide/protein antibodies is not synonymous with rheumatoid arthritis. A longterm followup study. <i>Journal of Rheumatology</i> , 2012 , 39, 1929-33	4.1	26
141	FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor- β blockers in psoriatic arthritis: a longitudinal study with 6 months of followup. <i>Journal of Rheumatology</i> , 2012 , 39, 1035-41	4.1	26
140	Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. <i>Pharmacogenetics and Genomics</i> , 2014 , 24, 238-45	1.9	25
139	Differences in synovial fluid cytokine levels but not in synovial tissue cell infiltrate between anti-citrullinated peptide/protein antibody-positive and -negative rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2013 , 15, R182	5.7	25
138	Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms. <i>Rheumatology</i> , 2010 , 49, 458-66	3.9	25
137	Development of ischemic complications in patients with giant cell arteritis presenting with apparently isolated polymyalgia rheumatica: study of a series of 100 patients. <i>Medicine (United States)</i> , 2007 , 86, 233-241	1.8	25
136	Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78,	2.4	25
135	Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. <i>Rheumatology</i> , 2018 , 57, 499-507	3.9	24
134	Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. <i>Rheumatology International</i> , 2016 , 36, 1043-63	3.6	24
133	Skin lesions and treatment with tumor necrosis factor alpha antagonists. <i>Reumatología Clínica</i> , 2013 , 9, 53-61	0.9	24
132	Toxoplasma gondii: bystander or cofactor in rheumatoid arthritis. <i>Immunologic Research</i> , 2013 , 56, 287-92	4.3	24
131	Morphea associated with the use of adalimumab: a case report and review of the literature. <i>Modern Rheumatology</i> , 2012 , 22, 602-604	3.3	24

130	Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 11	5.7	24
129	Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARDiovascular in rheuMATology study project. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 749-756.e3	4.9	23
128	Incidence of full-thickness rotator cuff tear after subacromial corticosteroid injection: a 12-week prospective study. <i>Modern Rheumatology</i> , 2014 , 24, 667-70	3.3	23
127	Synovial vascular patterns and angiogenic factors expression in synovial tissue and serum of patients with rheumatoid arthritis. <i>Rheumatology</i> , 2006 , 45, 966-71	3.9	23
126	Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study. <i>Rheumatology</i> , 2018 , 57, 688-693	3.9	22
125	Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions. <i>Reumatología Clínica</i> , 2014 , 10, 10-6	0.9	22
124	Safety profile of biological therapies for treating rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 1089-1103	5.4	22
123	Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 587-594	2.4	21
122	Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 935-6	2.4	21
121	Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial. <i>Rheumatology</i> , 2005 , 44, 1140-4	3.9	21
120	Tobacco and other environmental risk factors in rheumatoid arthritis. <i>Reumatología Clínica</i> , 2012 , 8, 342-50	0.9	20
119	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study. <i>Reumatología Clínica</i> , 2019 , 15, 102-108	0.9	20
118	Comparison of Dexketoprofen Trometamol and Ketoprofen in the Treatment of Osteoarthritis of the Knee. <i>Journal of Clinical Pharmacology</i> , 1998 , 38, 745-805	2.9	19
117	IL-6 blockade reverses the abnormal STAT activation of peripheral blood leukocytes from rheumatoid arthritis patients. <i>Clinical Immunology</i> , 2015 , 158, 174-82	9	18
116	Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists?. <i>Rheumatology</i> , 2011 , 50, 1523-5	3.9	18
115	Association of intermittent hydrarthrosis with MEFV gene mutations. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2334-5		18
114	Impact of Comorbidity on Physical Function in Patients With Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics: Results From a Cross-Sectional Study. <i>Arthritis Care and Research</i> , 2020 , 72, 822-828	4.7	18
113	Psoriatic Synovitis: Singularity and Potential Clinical Implications. <i>Frontiers in Medicine</i> , 2019 , 6, 14	4.9	16

112	Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. <i>Rheumatology</i> , 2015 , 54, 2239-43	3.9	16
111	CD271(+) stromal cells expand in arthritic synovium and exhibit a proinflammatory phenotype. <i>Arthritis Research and Therapy</i> , 2016 , 18, 66	5.7	16
110	Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study. <i>Rheumatology</i> , 2005 , 44, 1555-8	3.9	16
109	Abatacept use in rheumatoid arthritis: evidence review and recommendations. <i>Reumatología Clínica</i> , 2013 , 9, 5-17	0.9	15
108	A deletion at ADAMTS9-MAG11 locus is associated with psoriatic arthritis risk. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1875-81	2.4	15
107	The use of chimeric vimentin citrullinated peptides for the diagnosis of rheumatoid arthritis. <i>Journal of Medicinal Chemistry</i> , 2011 , 54, 7486-92	8.3	15
106	Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 41, 401-5	5.3	15
105	Recommendations of the Spanish Society of Rheumatology on treatment and use of systemic biological and non-biological therapies in psoriatic arthritis. <i>Reumatología Clínica</i> , 2018 , 14, 254-268	0.9	15
104	Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 962-975	3.8	14
103	Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e42	2.4	14
102	Is there subclinical synovitis in patients with palindromic rheumatism in the intercritical period? a clinical and ultrasonographic study according to anticitrullinated protein antibody status. <i>Journal of Rheumatology</i> , 2014 , 41, 1650-5	4.1	14
101	The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 613-24	4.1	14
100	Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. <i>Arthritis Research and Therapy</i> , 2018 , 20, 275	5.7	14
99	Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review. <i>Rheumatology International</i> , 2018 , 38, 975-983	3.6	13
98	Effectiveness of a clinical practice intervention in early rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012 , 64, 321-30	4.7	13
97	Clinical significance of high levels of soluble tumour necrosis factor- β receptor-2 produced by alternative splicing in rheumatoid arthritis: a longitudinal prospective cohort study. <i>Rheumatology</i> , 2011 , 50, 721-8	3.9	13
96	Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 716-725	3.8	12
95	Tocilizumab in the treatment of adult rheumatoid arthritis. <i>Immunotherapy</i> , 2018 , 10, 447-464	3.8	12

94	Accelerated nodulosis during methotrexate therapy in a patient with systemic lupus erythematosus and Jaccoud's arthropathy. <i>British Journal of Rheumatology</i> , 2004 , 43, 1587-8		12
93	A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2019 , 10, 1459	8.4	11
92	Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017 , 19, 141	5.7	11
91	Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. <i>PLoS ONE</i> , 2015 , 10, e0123392	3.7	11
90	Ultrasound evaluation of greater trochanter pain syndrome in patients with spondyloarthritis: are there any specific features?. <i>Rheumatology International</i> , 2014 , 34, 947-52	3.6	11
89	Palindromic rheumatism: a reappraisal. <i>International Journal of Clinical Rheumatology</i> , 2013 , 8, 569-577	1.5	11
88	Differential Antigen-presenting B Cell Phenotypes from Synovial Microenvironment of Patients with Rheumatoid and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2015 , 42, 1825-34	4.1	10
87	A genome-wide association study identifies SLC8A3 as a susceptibility locus for ACPA-positive rheumatoid arthritis. <i>Rheumatology</i> , 2016 , 55, 1106-11	3.9	10
86	Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 47, 303-309	5.3	9
85	Model of excellence in Rheumatology Day Hospitals in Spain: the HD-Reumatolex project. <i>Reumatología Clínica</i> , 2013 , 9, 142-7	0.9	9
84	Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial. <i>Trials</i> , 2015 , 16, 370	2.8	9
83	Biologic therapy in rheumatoid arthritis. <i>Current Topics in Medicinal Chemistry</i> , 2013 , 13, 752-9	3	9
82	Morphea associated with the use of adalimumab: a case report and review of the literature. <i>Modern Rheumatology</i> , 2012 , 22, 602-4	3.3	9
81	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021 , 117, 102580	15.5	9
80	Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study. <i>Arthritis Research and Therapy</i> , 2019 , 21, 88	5.7	8
79	Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1616-1625	9.5	8
78	Recommendations for the use of parenteral methotrexate in rheumatic diseases. <i>Reumatología Clínica</i> , 2018 , 14, 142-149	0.9	8
77	Macroscopic features of knee synovitis in early untreated Behçet disease and psoriatic arthritis. <i>Clinical Rheumatology</i> , 2009 , 28, 1053-7	3.9	8

76	REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients. <i>Heliyon</i> , 2017 , 3, e00452	3.6	7
75	Rheumatoid Arthritis Initiating as Palindromic Rheumatism: A Distinct Clinical Phenotype?. <i>Journal of Rheumatology</i> , 2020 , 47, 652-657	4.1	7
74	The Transcriptional Coactivator Bob1 Is Associated With Pathologic B Cell Responses in Autoimmune Tissue Inflammation. <i>Arthritis and Rheumatology</i> , 2017 , 69, 750-762	9.5	6
73	PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis. <i>Pharmacogenomics</i> , 2014 , 15, 1763-1769	2.6	6
72	Synthesis of overlapping fibrin citrullinated peptides and their use for diagnosing rheumatoid arthritis. <i>Chemical Biology and Drug Design</i> , 2006 , 68, 194-200	2.9	6
71	Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. <i>Rheumatology</i> , 2019 , 58, 1056-1064	3.9	6
70	EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1286-1298	2.4	6
69	Exposure-response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1710-1718 ^{3.8}	3.8	5
68	Laryngeal assessment by videolaryngostroboscopy in patients with rheumatoid arthritis. <i>Reumatología Clínica</i> , 2014 , 10, 32-6	0.9	5
67	Tackling missing radiographic progression data: multiple imputation technique compared with inverse probability weights and complete case analysis. <i>Rheumatology</i> , 2013 , 52, 331-6	3.9	5
66	Lung Sarcoidosis Induced by TNF Antagonists in Rheumatoid Arthritis: A Case Presentation and a Literature Review. <i>Archivos De Bronconeumología</i> , 2011 , 47, 208-212	0.7	5
65	Proliferative lupus nephritis in a patient with systemic lupus erythematosus and longstanding secondary amyloid nephropathy. <i>Clinical Rheumatology</i> , 2009 , 28, 95-7	3.9	5
64	Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X20978139	3.8	5
63	Diagnostic and therapeutic delay of rheumatoid arthritis and its relationship with health care devices in Catalonia. The AUDIT study. <i>Reumatología Clínica</i> , 2016 , 12, 146-50	0.9	5
62	Comparative study of the diagnostic and prognostic value of antibodies against chimeric citrullinated synthetic peptides and CCP3/CCP3.1 assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018 , 56, 285-293	5.9	4
61	Use of [Cit312,314] filaggrin (306B24) analogue for the diagnosis of rheumatoid arthritis. Conformational study by circular dichroism and fourier transformed infrared spectroscopy. <i>International Journal of Peptide Research and Therapeutics</i> , 2002 , 9, 291-300		4
60	Pseudogout masking brucellar arthritis. <i>Rheumatology</i> , 1995 , 34, 294-5	3.9	4
59	Genetic variation associated with cardiovascular risk in autoimmune diseases. <i>PLoS ONE</i> , 2017 , 12, e0185889	3.7	4

58	Lower peripheral helper T cell levels in the synovium are associated with a better response to anti-TNF therapy in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 196	5.7	4
57	Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e262-e269	14.2	4
56	GM-CSF Expression and Macrophage Polarization in Joints of Undifferentiated Arthritis Patients Evolving to Rheumatoid Arthritis or Psoriatic Arthritis. <i>Frontiers in Immunology</i> , 2020 , 11, 613975	8.4	4
55	Palindromic rheumatism: Evidence of four subtypes of palindromic-like arthritis based in either MEFV or rheumatoid factor/ACPA status. <i>Joint Bone Spine</i> , 2021 , 88, 105235	2.9	4
54	Variability in Rheumatology day care hospitals in Spain: VALORA study. <i>Reumatología Clínica</i> , 2017 , 13, 10-16	0.9	3
53	Development of a multiplex assay based on chimeric citrullinated peptides as proof of concept for diagnosis of rheumatoid arthritis. <i>PLoS ONE</i> , 2019 , 14, e0215927	3.7	3
52	2014 Update of the Consensus Statement of the Spanish Society of Rheumatology on the Use of Biological Therapies in Rheumatoid Arthritis. <i>Reumatología Clínica (English Edition)</i> , 2015 , 11, 279-294	0.1	3
51	Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 1417-1425	2.8	3
50	A composite indicator to assess the quality of care in the management of patients with rheumatoid arthritis in outpatient rheumatology clinics. <i>Reumatología Clínica</i> , 2019 , 15, 156-164	0.9	3
49	Efficacy and safety of glucocorticoids in rheumatoid arthritis: Systematic literature review. <i>Reumatología Clínica</i> , 2020 , 16, 222-228	0.9	3
48	Practical Aspects of Biological Thought Levels and Antidrug Antibodies in Rheumatoid Arthritis and Spondyloarthritis. <i>Reumatología Clínica</i> , 2020 , 16, 378-385	0.9	3
47	Biomarkers for treatment change and radiographic progression in patients with rheumatoid arthritis in remission: a 5 year follow-up study. <i>Rheumatology</i> , 2021 , 60, 667-674	3.9	3
46	Palindromic Rheumatism: Just a Pre-rheumatoid Stage or Something Else?. <i>Frontiers in Medicine</i> , 2021 , 8, 657983	4.9	3
45	The synovial and blood monocyte DNA methylomes mirror prognosis, evolution and treatment in early arthritis.. <i>JCI Insight</i> , 2022 ,	9.9	3
44	Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs in rheumatoid arthritis: results of the GO-MORE study in Spain. <i>Reumatología Clínica</i> , 2015 , 11, 144-50	0.9	2
43	Antibodies against Fibrin synthetic peptides: a study of their association with the immunogenetic background and disease course of rheumatoid arthritis patients. <i>European Journal of Medicinal Chemistry</i> , 2011 , 46, 1095-102	6.8	2
42	Determination of soluble tumor necrosis factor receptor 2 produced by alternative splicing. <i>Methods in Molecular Biology</i> , 2014 , 1155, 187-99	1.4	2
41	Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis. <i>Reumatología Clínica</i> , 2020 , 18, 33-33	0.9	2

40	Palindromic rheumatism: a unique and enigmatic entity with a complex relationship with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 375-384	5.1	2
39	Synovial Immunohistological Biomarkers of the Classification of Undifferentiated Arthritis Evolving to Rheumatoid or Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 2021 , 8, 656667	4.9	2
38	Ultrasound findings in palindromic rheumatism. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e30	2.4	2
37	Efficacy and Safety of Combined Therapy With Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Systematic Literature Review. <i>Reumatología Clínica</i> , 2020 , 16, 324-332	0.9	2
36	Prevalence of Comorbidities in Rheumatoid Arthritis and Evaluation of Their Monitoring in Clinical Practice: The Spanish Cohort of the COMORA Study. <i>Reumatología Clínica (English Edition)</i> , 2019 , 15, 102-108	0.1	1
35	Sustained response to rituximab in a TNFi-induced ANCA-vasculitis developed in a patient with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, e15-e16	5.3	1
34	Measuring inflammation in rheumatoid arthritis with a new clinical and ultrasound index: development and initial validation. <i>Rheumatology International</i> , 2019 , 39, 2137-2145	3.6	1
33	Skin Lesions and Treatment With Tumor Necrosis Factor Alpha Antagonists. <i>Reumatología Clínica (English Edition)</i> , 2013 , 9, 53-61	0.1	1
32	Laryngeal Assessment by Videolaryngostroboscopy in Patients With Rheumatoid Arthritis. <i>Reumatología Clínica (English Edition)</i> , 2014 , 10, 32-36	0.1	1
31	Tobacco and Other Environmental Risk Factors in Rheumatoid Arthritis. <i>Reumatología Clínica (English Edition)</i> , 2012 , 8, 342-350	0.1	1
30	Brucelosis humana. Características clínicas con énfasis en las manifestaciones osteoarticulares. <i>Seminarios De La Fundación Española De Reumatología</i> , 2005 , 6, 93-102		1
29	Use of [Cit312,314] filaggrin (306B24) analogue for the diagnosis of rheumatoid arthritis. Conformational study by circular dichroism and fourier transformed infrared spectroscopy. <i>International Journal of Peptide Research and Therapeutics</i> , 2002 , 9, 291-300		1
28	Analytical and clinical evaluation of DiaSorin Liaison [®] Calprotectin fecal assay adapted for serum samples.. <i>Journal of Clinical Laboratory Analysis</i> , 2022 , e24258	3	1
27	Tc-99m labeled nonspecific polyclonal human immunoglobulin G taken up by a uterine myoma. <i>Clinical Nuclear Medicine</i> , 1997 , 22, 273-4	1.7	1
26	Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. <i>European Journal of Clinical Nutrition</i> , 2021 , 75, 1368-1382	5.2	1
25	Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy. <i>BMC Musculoskeletal Disorders</i> , 2021 , 22, 372	2.8	1
24	Expert Recommendations on the Interleukin 6 Blockade in Patients with Rheumatoid Arthritis. <i>Reumatología Clínica</i> , 2020 , 16, 272-281	0.9	1
23	Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure. <i>Reumatología Clínica</i> , 2020 , 16, 345-352	0.9	1

22	Assessing treatment tolerability for rheumatoid arthritis. Validation and practical applications of the FOL-AR-18 questionnaire. <i>Reumatología Clínica</i> , 2020 , 16, 149-155	0.9	1
21	Recommendations of the Spanish Society of Rheumatology on Treatment and Use of Systemic Biological and Non-biological Therapies in Psoriatic Arthritis. <i>Reumatología Clínica (English Edition)</i> , 2018 , 14, 254-268	0.1	1
20	Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study.. <i>Clinical Rheumatology</i> , 2022 , 1	3.9	1
19	Efficacy and safety of combined therapy with synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: Systematic literature review. <i>Reumatología Clínica (English Edition)</i> , 2020 , 16, 324-332	0.1	0
18	Longitudinal analysis of blood DNA methylation identifies mechanisms of response to tumor necrosis factor inhibitor therapy in rheumatoid arthritis.. <i>EBioMedicine</i> , 2022 , 80, 104053	8.8	0
17	Variability in Rheumatology Day Care Hospitals in Spain: VALORA Study. <i>Reumatología Clínica (English Edition)</i> , 2017 , 13, 10-16	0.1	
16	Reply. <i>Arthritis Care and Research</i> , 2017 , 69, 606-607	4.7	
15	Anti-citrullinated peptide/protein antibodies in palindromic rheumatism: comment on the article by Emad Y et al. <i>Clinical Rheumatology</i> , 2015 , 34, 613-4	3.9	
14	Recommendations for the Use of Parenteral Methotrexate in Rheumatic Diseases. <i>Reumatología Clínica (English Edition)</i> , 2018 , 14, 142-149	0.1	
13	Musculoskeletal Involvement in Hereditary Hemochromatosis. <i>Journal of Clinical Rheumatology</i> , 2017 , 23, 291	1.1	
12	Radiographic progression in early rheumatoid arthritis: comment on the article by Goronzy et al. <i>Arthritis and Rheumatism</i> , 2004 , 50, 3052-3; author reply 3053-4		
11	Experts document on methotrexate use in combined therapy with biological or targeted synthetic disease modifying drugs in patients with rheumatoid arthritis.. <i>Reumatología Clínica (English Edition)</i> , 2022 , 18, 33-41	0.1	
10	Psoriatic Arthritis: A Current Vision 2019 , 105-105		
9	Effects of smoking on the clinical phenotype and response to treatment in rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2013 , 8, 221-231	1.5	
8	Practical aspects of biological through levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis. <i>Reumatología Clínica (English Edition)</i> , 2020 , 16, 378-385	0.1	
7	Expert recommendations on the interleukin 6 blockade in patients with rheumatoid arthritis. <i>Reumatología Clínica (English Edition)</i> , 2020 , 16, 272-281	0.1	
6	Efficacy and safety of glucocorticoids in rheumatoid arthritis: Systematic literature review. <i>Reumatología Clínica (English Edition)</i> , 2020 , 16, 222-228	0.1	
5	Is Auto-Antibody Expansion the Turning Point Between Idiopathic Pulmonary Fibrosis and Rheumatoid Arthritis?. <i>Chest</i> , 2020 , 158, 1777-1778	5.3	

- | | | |
|---|---|-----|
| 4 | Comparable long-term outcomes between DAS28-ESR remission criteria and ACR/EULAR definitions in patients with established rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021 , 40, 2665-2672 ^{3,9} | |
| 3 | How do Spanish Rheumatologists Handle Referral? Survey of Knowledge and Approach Before and After a Training Workshop. <i>Reumatología Clínica</i> , 2021 , | 0.9 |
| 2 | Anti-carbamylated protein antibodies are associated with early abatacept response in rheumatoid arthritis. Comment on: Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 1142-1143 | 2.2 |
| 1 | How do Spanish Rheumatologists handle referral? Survey of knowledge and approach before and after a training workshop.. <i>Reumatología Clínica (English Edition)</i> , 2021 , | 0.1 |